Gsa Capital Partners LLP Rapt Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$2.89 - $9.38 $105,930 - $343,814	36,654 New	36,654 $112,000
Q4 2023 Feb 16, 2024	SELL	$11.28 - $25.46 $115,969 - $261,754	-10,281 Reduced 33.47%	20,435 $507,000
Q3 2023 Nov 15, 2023	SELL	$16.34 - $24.66 $72,288 - $109,095	-4,424 Reduced 12.59%	30,716 $510,000
Q2 2023 Aug 14, 2023	BUY	$16.06 - $21.61 $76,734 - $103,252	4,778 Added 15.74%	35,140 $657,000
Q1 2023 May 12, 2023	BUY	$17.19 - $30.8 $521,922 - $935,149	30,362 New	30,362 $557,000
Q3 2022 Nov 14, 2022	BUY	$17.96 - $30.46 $480,789 - $815,414	26,770 Added 240.72%	37,891 $912,000
Q2 2022 Aug 09, 2022	SELL	$10.26 - $23.59 $79,966 - $183,860	-7,794 Reduced 41.21%	11,121 $203,000
Q1 2022 May 11, 2022	BUY	$17.02 - $40.22 $172,429 - $407,468	10,131 Added 115.33%	18,915 $416,000
Q4 2021 Feb 14, 2022	SELL	$29.5 - $39.5 $726,850 - $973,240	-24,639 Reduced 73.72%	8,784 $323,000
Q3 2021 Nov 12, 2021	BUY	$29.86 - $39.47 $998,010 - $1.32 Million	33,423 New	33,423 $1.04 Million

104

27.1M

26.7K

2.4K

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $36.5M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.